TY - JOUR
T1 - European enhanced surveillance of invasive pneumococcal disease in 2010
T2 - Data from 26 European countries in the post-heptavalent conjugate vaccine era
AU - Torné, Adoración Navarro
AU - Dias, Joana Gomes
AU - Quinten, Chantal
AU - Hruba, Frantiska
AU - Busana, Marta Cecilia
AU - Lopalco, Pier Luigi
AU - Gauci, Andrew J.Amato
AU - Pastore-Celentano, Lucia
AU - Sabbe, Martine
AU - Verhaegen, Jan
AU - Koliou, Maria
AU - Pieridou-Bagkatzouni, Despo
AU - Křižovà, Pavla
AU - Kozakova, Jana
AU - Motlova, Jitka
AU - Valentiner-Branth, Palle
AU - Lambertsen, Lotte
AU - Georgakopoulou, Theano
AU - Humphreys, Hilary
AU - Melillo, Tanya
AU - Caruana, Paul
AU - Knol, Mirjam
AU - de Merkel, Hester
AU - Elberse, Karin
AU - Frimann, Didrik
AU - Skoczynska, Anna
AU - Hryniewicz, Waleria
AU - Kuch, Alicja
AU - Paradowska-Stankiewicz, Iwona
AU - Pana, Marina
AU - Vitek, Marta
AU - Učakar, Veronika
AU - Normark, Birgitta Henriques
AU - Lepp, Tiia
AU - Slack, Mary
AU - Waight, Pauline A.
PY - 2014/6/17
Y1 - 2014/6/17
N2 - Streptococcus pneumoniae is a leading cause of severe infectious diseases worldwide. This paper presents the results from the first European invasive pneumococcal disease (IPD) enhanced surveillance where additional and valuable data were reported and analysed. Following its authorisation in Europe in 2001 for use in children aged between two months and five years, the heptavalent pneumococcal conjugate vaccine (PCV7) was progressively introduced in the European Union (EU)/European Economic Area (EEA) countries, albeit with different schemes and policies. In mid-2010 European countries started to switch to a higher valency vaccine (PCV10/PCV13), still without a significant impact by the time of this surveillance. Therefore, this surveillance provides an overview of baseline data from the transition period between the introduction of PCV7 and the implementation of PCV10/PCV13.In 2010, 26 EU/EEA countries reported 21 565 cases of IPD to The European Surveillance System (TESSy) applying the EU 2008 case definition. Serotype was determined in 9. 946/21. 565 (46.1%) cases. The most common serotypes were 19A, 1, 7F, 3, 14, 22F, 8, 4, 12F and 19F, accounting for 5. 949/9. 946 (59.8%) of the serotyped isolates. Data on antimicrobial susceptibility testing (AST) in the form of minimum inhibitory concentrations (MIC) were submitted for penicillin 5. 384/21. 565 (25.0%), erythromycin 4. 031/21. 565 (18.7%) and cefotaxime 5. 252/21. 565 (24.4%). Non-susceptibility to erythromycin was highest at 17.6% followed by penicillin at 8.9%.PCV7 serotype coverage among children <5 years in Europe, was 19.2%; for the same age group, the serotype coverage for PCV10 and PCV13 were 46.1% and 73.1%, respectively.In the era of pneumococcal conjugate vaccines, the monitoring of changing trends in antimicrobial resistance and serotype distribution are essential in assessing the impact of vaccines and antibiotic use control programmes across European countries.
AB - Streptococcus pneumoniae is a leading cause of severe infectious diseases worldwide. This paper presents the results from the first European invasive pneumococcal disease (IPD) enhanced surveillance where additional and valuable data were reported and analysed. Following its authorisation in Europe in 2001 for use in children aged between two months and five years, the heptavalent pneumococcal conjugate vaccine (PCV7) was progressively introduced in the European Union (EU)/European Economic Area (EEA) countries, albeit with different schemes and policies. In mid-2010 European countries started to switch to a higher valency vaccine (PCV10/PCV13), still without a significant impact by the time of this surveillance. Therefore, this surveillance provides an overview of baseline data from the transition period between the introduction of PCV7 and the implementation of PCV10/PCV13.In 2010, 26 EU/EEA countries reported 21 565 cases of IPD to The European Surveillance System (TESSy) applying the EU 2008 case definition. Serotype was determined in 9. 946/21. 565 (46.1%) cases. The most common serotypes were 19A, 1, 7F, 3, 14, 22F, 8, 4, 12F and 19F, accounting for 5. 949/9. 946 (59.8%) of the serotyped isolates. Data on antimicrobial susceptibility testing (AST) in the form of minimum inhibitory concentrations (MIC) were submitted for penicillin 5. 384/21. 565 (25.0%), erythromycin 4. 031/21. 565 (18.7%) and cefotaxime 5. 252/21. 565 (24.4%). Non-susceptibility to erythromycin was highest at 17.6% followed by penicillin at 8.9%.PCV7 serotype coverage among children <5 years in Europe, was 19.2%; for the same age group, the serotype coverage for PCV10 and PCV13 were 46.1% and 73.1%, respectively.In the era of pneumococcal conjugate vaccines, the monitoring of changing trends in antimicrobial resistance and serotype distribution are essential in assessing the impact of vaccines and antibiotic use control programmes across European countries.
KW - Antimicrobial resistance
KW - Europe
KW - Invasive pneumococcal disease
KW - Pneumococcal vaccines
KW - Serotype
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=84901596757&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2014.04.066
DO - 10.1016/j.vaccine.2014.04.066
M3 - Article
C2 - 24795228
AN - SCOPUS:84901596757
SN - 0264-410X
VL - 32
SP - 3644
EP - 3650
JO - Vaccine
JF - Vaccine
IS - 29
ER -
